Rallybio (RLYB) has issued an update.
Martin Mackay, Ph.D., has announced his intention to step down as Executive Chairman of Rallybio Corporation by the end of 2024 but will continue to serve on the Board as Chairman. He will not receive severance but is set to begin a consultancy role with the company starting January 1, 2025, for at least a year, with a monthly fee of $18,750. This agreement includes provisions for the continuation of equity award vesting and terms for immediate vesting in the event of a company takeover.
For an in-depth examination of RLYB stock, go to TipRanks’ Stock Analysis page.
